Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder.

Objective: To review the pharmacology, pharmacokinetics, and efficacy and safety data of a combination of olanzapine and samidorphan (OLZ/SAM) for the treatment of schizophrenia and bipolar I disorder, which mitigates the possible unwanted side effects of weight gain associated with olanzapine (OLZ).

Data Sources: The review was done with a bibliographic survey of studies using MEDLINE/PubMed (January 1999-May 2021) database using the keywords olanzapine and samidorphan. Abstracts, scientific posters, and information from the manufacturer's product labeling were evaluated for inclusion.

Lumateperone: A Novel Antipsychotic for Schizophrenia.

Objective: To provide a concise review of the new Food and Drug Administration (FDA)-approved antipsychotic, lumateperone, for use in schizophrenia.

Data Sources: A literature search of PubMed was performed (January 2000 to May 2020) using the following key terms: , and . Abstracts from conferences, review articles, clinical trials, and drug monographs were reviewed.

Perseris: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.

Perseris: A new, long-acting, atypical antipsychotic drug-delivery system.

Intranasal Esketamine (Spravato) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant.

Intranasal esketamine for treatment-resistant depression.

Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.

Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia.

Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women.

Flibanserin (Addyi) for female sexual interest/arousal disorder in premenopausal women.

Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder.

Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent.

Paliperidone palmitate three-month injection (Invega Trinza): the first four-times-a-year, long-acting injectable antipsychotic agent for schizophrenia.

Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.

Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.

Cognitive and Performance Enhancing Medication Use to Improve Performance in Poker.

Use of neuroenhancers has been studied in groups ranging from students to surgeons; however, use of cognitive and performance enhancing medications (CPEMs) to improve performance in poker has remained largely overlooked. To assess the use of CPEMs to improve poker performance, a survey of poker players was conducted. Participants were recruited via Internet poker forums; 198 completed the online survey.

Vortioxetine (brintellix): a new serotonergic antidepressant.

Vortioxetine (Brintellix): a new serotonergic antidepressant.

Loxapine inhalation powder (adasuve): a new and innovative formulation of an antipsychotic treatment for agitation.

Loxapine inhalation powder (Adasuve): an innovative formulation of an antipsychotic treatment for agitation.

Phentermine/Topiramate extended-release capsules (qsymia) for weight loss.

Phentermine/topiramate extended-release capsules (Qsymia) for weight loss.

Prevalence of hazardous alcohol use among pharmacy students at nine U.S. schools of pharmacy.

Unlabelled: Hazardous use of alcohol continues to be recognized as a problem at the university level. Knowledge regarding alcohol consumption in healthcare professional students is limited, especially in regards to pharmacy students. Much of the information available focuses on pharmacy student drinking patterns in specific geographic regions or is simply outdated.

Atypical antipsychotics in children with pervasive developmental disorders.

The treatment of pervasive developmental disorders (PDDs) is a challenging task, which should include behavioral therapy modifications as well as pharmacologic therapy. There has been a lack of data on using medications in children with PDDs until recent years. Within the last 10 years, an increase in clinical research has attempted to provide efficacy and safety data to support the use of medications in children with PDDs.

Role of risperidone in children with autism spectrum disorder.

Objective: To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD).

Data Sources: Searches of MEDLINE/PubMed (1992-February 2006) were conducted, as well as an extensive manual review of journals, using the key words autism and risperidone.

Study Selection And Data Extraction: Only double-blind, placebo-controlled trials were included for review.

Antipsychotic therapy: a pharmacoeconomic perspective.

The pharmacoeconomics of antipsychotic therapy is discussed. Schizophrenia is a chronic illness that develops early in life and has a long-term impact on the health care system, including costs. Treatment goals therefore include a reduction in the rate of rehospitalization, a primary source of the health care costs related to this disease.

The discovery and status of sibutramine as an anti-obesity drug.

Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet. Though sibutramine was originally evaluated for possible use as an antidepressant, its research development was eventually redirected to evaluate it as an anorexiant. The pharmacological mechanisms by which sibutramine exerts its weight loss effect are likely due to a combination of reduced appetite, feelings of satiety, and possibly the induction of thermogenesis.